Celaid Therapeutics Secures Additional Funding for Innovative HSC Therapy Development
Celaid Therapeutics Secures Additional Funding for Innovative HSC Therapy Development
Celaid Therapeutics Inc., based in Bunkyo-ku, Tokyo, has successfully completed the second close of its Series B financing round, raising JPY 400 million (approximately USD 2.6 million). This financing round has attracted significant attention from new investors, including prominent pharmaceutical companies Shionogi Co., Ltd. and Teikoku Ventures, Inc., which highlights the growing interest in Celaid's innovative approaches to treating severe pediatric non-malignant diseases.
Financial Milestone and Strategic Support
With the latest influx of funds, Celaid's total cumulative capital raised now stands at approximately JPY 3.42 billion (around USD 22.1 million), including grants from various support programs. Notably, the company's progress has garnered approval from the Japan Agency for Medical Research and Development (AMED), which selected Celaid for Stage 3 funding under its
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.